TABLE 2.
Performances of 10 rapid serological tests for SARS-CoV-2 antibodies in Paris, France, in June 2020
| Test | Total no. of samples tested | No of test results that were not interpretable | Sensitivity |
Specificity |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of samplesa | Ig type | Sensitivity by time elapsed after symptom onset (%) (CI95) |
No. of samples testedb | Ig type | Specificity (%) (CI95) | |||||
| 0–9 days | 10–14 days | >14 days | ||||||||
| RDT 1 (IgM/IgG) | 499 | 0 | 247 | IgM or IgG | 42.0 (32.3–52.3) | 75.0 (64.1–83.5) | 93.7 (83.7–97.9) | 252 | IgM or IgG | 99.2 (96.9–99.9) |
| IgM | 42.0 (32.3–52.3) | 75.0 (64.1–83.5) | 93.7 (83.7–97.9) | IgM | 99.6 (97.5–100.0) | |||||
| IgG | 33.0 (24.1–43.2) | 70.2 (59.1–79.5) | 85.7 (74.1–92.9) | IgG | 99.2 (96.9–99.9) | |||||
| RDT 2 (IgM/IgG) | 500 | 0 | 247 | IgM or IgG | 52.0 (41.8–62.0) | 87.1 (77.6–93.1) | 90.3 (79.5–96.0) | 253 | IgM or IgG | 94.5 (90.7–96.8) |
| IgM | 46.0 (36.1–56.2) | 81.2 (70.9–88.5) | 82.3 (70.0–90.4) | IgM | 96.0 (92.6–98.0) | |||||
| IgG | 44.0 (34.2–54.3) | 83.5 (73.6–90.4) | 83.9 (71.9–91.6) | IgG | 97.6 (94.7–99.0) | |||||
| RDT 3 (IgM/IgG) | 482 | 1 | 243 | IgM or IgG | 46.5 (36.6–56.7) | 76.5 (65.6–84.9) | 91.8 (81.2–96.9) | 238 | IgM or IgG | 94.1 (90.1–96.6) |
| IgM | 42.6 (32.9–52.8) | 75.3 (64.3–83.9) | 86.9 (75.2–93.8) | IgM | 95.4 (91.7–97.6) | |||||
| IgG | 45.5 (35.7–55.7) | 75.3 (64.3–83.9) | 91.8 (81.2–96.9) | IgG | 95.8 (92.2–97.9) | |||||
| RDT 4 (IgM/IgG) | 503 | 0 | 249 | IgM or IgG | 55.4 (45.2–65.2) | 90.6 (81.8–95.6) | 92.1 (81.7–97.0) | 254 | IgM or IgG | 99.2 (96.9–99.9) |
| IgM | 54.5 (44.3–64.3) | 88.2 (79.0–93.9) | 90.5 (79.8–96.1) | IgM | 100.0 (98.1–100) | |||||
| IgG | 18.8 (12.0–28.1) | 54.1 (43.0–64.9) | 90.5 (79.8–96.1) | IgG | 99.2 (96.9–99.9) | |||||
| RDT 5 (IgM/IgG) | 495 | 0 | 246 | IgM or IgG | 48.0 (38.0–58.2) | 84.3 (74.3–91.1) | 90.5 (79.8–96.1) | 249 | IgM or IgG | 92.4 (83.6–96.9) |
| IgM | 48.0 (38.0–58.2) | 80.7 (70.3–88.3) | 90.5 (79.8–96.1) | IgM | 97.5 (90.3–99.6) | |||||
| IgG | 22.0 (14.6–31.6) | 69.9 (58.7–79.2) | 77.8 (65.2–86.9) | IgG | 94.9 (86.9–98.4) | |||||
| RDT 6 (IgM/IgG) | 502 | 0 | 249 | IgM or IgG | 31.7 (23.0–41.8) | 65.9 (54.7–75.6) | 81.0 (68.7–89.4) | 253 | IgM or IgG | 98.4 (95.7–99.5) |
| IgM | 22.8 (15.3–32.4) | 54.1 (43.0–64.9) | 61.9 (48.8–73.6) | IgM | 99.2 (96.9–99.9) | |||||
| IgG | 21.8 (14.4–31.3) | 60.0 (48.8–70.3) | 71.4 (58.5–81.8) | IgG | 98.8 (96.3–99.7) | |||||
| RDT 7 (IgM/IgG)c | 246 | 0 | 167 | IgM or IgG | 35.7 (24.9–48.1) | 78.8 (64.9–88.5) | 93.3 (80.7–98.3) | 79 | IgM or IgG | 92.4 (83.6–96.7) |
| IgM | 20.0 (11.7–31.6) | 32.7 (20.7–47.3) | 53.3 (38.0–68.1) | IgM | 97.5 (90.3–99.6) | |||||
| IgG | 32.9 (22.4–45.2) | 76.9 (62.8–87.0) | 93.3 (80.7–98.3) | IgG | 94.9 (86.9–98.4) | |||||
| RDT 8 (IgM/IgG) | 488 | 3 | 238 | IgM or IgG | 55.7 (45.2–65.6) | 81.3 (70.6–88.8) | 88.5 (77.2–94.9) | 247 | IgM or IgG | 75.7 (69.8–80.8) |
| IgM | 42.3 (32.4–52.7) | 70.0 (58.6–79.5) | 65.6 (52.2–77.0) | IgM | 79.8 (74.1–84.5) | |||||
| IgG | 46.4 (36.3–56.8) | 71.3 (59.9–80.5) | 85.2 (73.3–92.6) | IgG | 87.9 (83.0–91.5) | |||||
| RDT 9 (total Ig) | 500 | 0 | 249 | Total Ig | 55.4 (45.2–65.2) | 92.9 (84.7–97.1) | 95.2 (85.8–98.8) | 251 | Total Ig | 98.4 (95.7–99.4) |
| RDT 10 (total Ig) | 503 | 0 | 249 | Total Ig | 55.4 (45.2–65.2) | 92.9 (84.7–97.1) | 92.1 (81.7–97.0) | 254 | Total Ig | 96.5 (93.2–98.3) |
a
Number of tested serum samples from COVID-positive patients.
b
Number of tested serum samples from COVID-negative patient.
c
RDT 7 was evaluated on only half of the total serum samples collection (only 250 tests received).